首页>
外国专利>
FUSION GENE OF KIF5B GENE AND RET GENE, AND METHOD FOR DETERMINING EFFECTIVENESS OF CANCER TREATMENT TARGETING FUSION GENE
FUSION GENE OF KIF5B GENE AND RET GENE, AND METHOD FOR DETERMINING EFFECTIVENESS OF CANCER TREATMENT TARGETING FUSION GENE
展开▼
机译:KIF5B基因和RET基因的融合基因,以及确定靶向靶向融合基因的癌症疗效的方法
展开▼
页面导航
摘要
著录项
相似文献
摘要
In order to identify a gene that can serve as an indicator for predicting the effectiveness of a drug treatment of cancer and to provide a novel method for predicting the effectiveness of a drug treatment targeting said gene, lung adenocarcinomas were subjected to whole-transcriptome sequencing. As a result, in-frame fusion transcripts between the KIF5B gene and the RET gene were identified. The KIF5B-RET gene fusions were detected in 6 out of 319 (2%) LADC specimens from Japanese individuals and 1 out of 80 (1%) LADC specimens from U.S.A. individuals. None of the seven subjects revealed known activating mutations such as EGFR, KRAS or ALK oncogenes; thus, said gene fusions were found to be responsible mutations (driver mutations) for oncogenesis. Since said gene fusions are considered to induce constitutive activation of RET tyrosine kinase protein, it was found that treatments with RET tyrosine kinase inhibitors are effective in patients with detection of said gene fusions.
展开▼